Meeting Expectations with Steady Growth- Trend to Continue
Soliris uptake in patients for Paroxysmal Nocturnal Hemoglobinuria (PNH) and accelerated approval in atypical Hemolytic Uremic Syndrome (aHUS) validate the long term potential of the drug. In upcoming scientific conference American Society of Nephrology (Nov. 8th to 13th) ALXN will present multiple data, showing potential of eculizumab in other indications targeting rare and high unmet need along with approved indication… For more details, please read our report released on October 21, 2011 on Alexion (ALXN), titled “Meeting Expectations with Steady Growth- Trend to Continue”.
COMPANIES MENTIONED
Alexion, Biogen Idec, Celgene, Gilead
Alexion, Biogen Idec, Celgene, Gilead
